Stockscreener 앱 받기
38.85
1.60%
0.61
전일 마감가:
$38.24
열려 있는:
$38.01
하루 거래량:
3.72M
Relative Volume:
1.97
시가총액:
$7.98B
수익:
-
순이익/손실:
$-505.61M
주가수익비율:
-14.03
EPS:
-2.7697
순현금흐름:
$-407.32M
1주 성능:
+9.93%
1개월 성능:
+14.84%
6개월 성능:
+48.51%
1년 성능:
+137.03%
1일 변동 폭
$37.51
$39.28
1주일 범위
$35.95
$39.28
52주 변동 폭
$14.32
$39.28
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
38.85 | 7.98B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I - GuruFocus
Avoiding Lag: Real-Time Signals in (IMVT) Movement - Stock Traders Daily
Immunovant CTO Jay Stout sells $1.53m in company stock By Investing.com - Investing.com Nigeria
Form 4 Immunovant Inc For: 26 June By Investing.com - Investing.com Australia
Immunovant chief legal officer sells $682,886 in stock - Investing.com
Immunovant (IMVT) CFO exercises options, sells 10,000 shares at ~$38 average - Stock Titan
Immunovant COO Melanie Gloria sells $678k in company stock By Investing.com - Investing.com South Africa
Immunovant director Atul Pande sells $57,015 in stock By Investing.com - Investing.com Canada
Immunovant (IMVT) COO sells 17,714 shares, keeps 224,393 stake - Stock Titan
Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades - Stock Titan
Immunovant (IMVT) Chief Legal Officer sells 17,824 shares after option exercise - Stock Titan
Immunovant (IMVT) director sells 1,500 shares after option exercise - Stock Titan
Form 144 IMMUNOVANT For: 26 June By Investing.com - Investing.com India
Insider Sale: President & Immunovant CEO of $ROIV Sells 46,234 Shares - Quiver Quantitative
IMVT (NASDAQ) Form 144 lists multiple vested restricted stock blocks, 40,000 header - Stock Titan
IMVT (NASDAQ: IMVT) files Form 144 for 17,824-share sale after option exercise - Stock Titan
[144] Immunovant, Inc. SEC Filing - Stock Titan
Immunovant Inc Actuals & Estimates (NASDAQ:IMVT) - TradingView
Price to sales forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView
IMVT Forecast — Price Target — Prediction for 2027 - TradingView
Immunovant (IMVT) up 3.6% since last earnings report: Can it continue? - MSN
Immunovant (IMVT) CLO mandated share sale to cover RSU tax withholding - Stock Titan
Immunovant stock hits 52-week high at 36.39 USD By Investing.com - Investing.com Australia
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Immunovant stock hits 52-week high at 36.39 USD - Investing.com
Immunovant Stockweekly view after recent volatility - Ad-hoc-news.de
Immunovant stock gains 12.4% in a month: What's driving it? - MSN
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunovant Inc (IMVT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immunovant Inc (IMVT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immunovant Inc (IMVT) Institutional Confidence - TradingKey
Immunovant Inc (IMVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunovant Inc (IMVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunovant Inc (IMVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan - Stock Titan
Discipline and Rules-Based Execution in IMVT Response - Stock Traders Daily
IMVT (NASDAQ: IMVT) files Form 144 reporting 6,000-share option exercise sale - Stock Titan
Immunovant Q4 earnings call highlights - MSN
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - The Globe and Mail
Immunovant Q4 2026 earnings preview - MSN
Immunovant Inc stock (US45258Q1058): shares trade around mid-30 USD ahead of next catalysts - AD HOC NEWS
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary - Yahoo Finance
Behavioral Patterns of IMVT and Institutional Flows - Stock Traders Daily
IMVT Technical Analysis & Stock Price Forecast - Intellectia AI
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data - Insider Monkey
13 Best Short Squeeze Stocks to Invest In - Insider Monkey
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Jun 26 '26 |
Sale |
38.31 |
40,000 |
1,532,309 |
211,685 |
| Van Tuyl Christopher | Chief Legal Officer |
Jun 26 '26 |
Option Exercise |
15.20 |
17,824 |
270,925 |
198,421 |
| Van Tuyl Christopher | Chief Legal Officer |
Jun 26 '26 |
Sale |
38.31 |
17,824 |
682,887 |
180,597 |
| Girao Tiago | Chief Financial Officer |
Jun 26 '26 |
Option Exercise |
15.90 |
10,000 |
159,000 |
257,596 |
| Girao Tiago | Chief Financial Officer |
Jun 26 '26 |
Sale |
38.46 |
10,000 |
384,600 |
247,596 |
| Pande Atul | Director |
Jun 26 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jun 26 '26 |
Sale |
38.01 |
1,500 |
57,015 |
116,731 |
1.36%
자본화:
|
볼륨(24시간):